KDM1A and acute promyelocytic leukemia: It was demonstrated that the treatment with LSD1 inhibitors of cells of Acute Promyelocytic Leukemia (APL), a subtype of AML, does not induce growth arrest but increase sensitivity of the same cells to physiological concentrations of RA (Binda et al., 2010).